[18F]AlF-NOTA-LM3在分化良好的神经内分泌肿瘤患者中的安全性、生物分布与剂量学评估,以及与[68Ga]Ga-DOTATATE的头对头比较:一项前瞻性试验的中期分析
该前瞻性试验中期分析纳入21例组织学确诊的分化良好(G1和G2)神经内分泌肿瘤患者,评估[18F]AlF-NOTA-LM3的安全性、生物分布与剂量学,并与[68Ga]Ga-DOTATATE进行头对头比较。结果显示[18F]AlF-NOTA-LM3安全且耐受良好,平均有效剂量为0.024 ± 0.014 mSv/MBq,在肝脏病灶(457 vs. 291,P = 0.006)和淋巴结病灶(30 vs. 22,P = 0.011)的检出数量上显著多于[68Ga]Ga-DOTATATE。
要点
- [18F]AlF-NOTA-LM3安全且耐受良好,平均有效剂量为0.024 ± 0.014 mSv/MBq。
- [18F]AlF-NOTA-LM3检出的肝脏病灶(457 vs. 291,P = 0.006)和淋巴结病灶(30 vs. 22,P = 0.011)显著多于[68Ga]Ga-DOTATATE。
- 除十二指肠外,[18F]AlF-NOTA-LM3在所有部位病灶的肿瘤/本底比值(TBR)均显著高于[68Ga]Ga-DOTATATE。
核心结论
- [18F]AlF-NOTA-LM3生物分布良好、空间分辨率更高,在检测肝和淋巴结转移方面优于[68Ga]Ga-DOTATATE,且TBR更高。
- 值得注意的是,它是首个在与[68Ga]Ga-DOTATATE比较中显示在检测淋巴结病灶方面具有优势的SSTR类似物。
研究设计与样本
- 前瞻性试验中期分析,纳入21例组织学确诊的分化良好(G1和G2)神经内分泌肿瘤患者。
- 前8例患者在注射[18F]AlF-NOTA-LM3后5、15、30、45、60和120分钟进行系列PET扫描以评估生物分布和剂量学,其余患者接受全身PET/CT扫描。
- [18F]AlF-NOTA-LM3和[68Ga]Ga-DOTATATE PET/CT在一周内完成,两次扫描间隔至少24小时。
主要发现
- [18F]AlF-NOTA-LM3安全且耐受良好。
- [18F]AlF-NOTA-LM3在腹部器官和骨髓的生理性摄取显著低于[68Ga]Ga-DOTATATE,但在血池和肺中更高。
- 平均有效剂量为0.024 ± 0.014 mSv/MBq。
- [18F]AlF-NOTA-LM3检出的肝脏病灶数显著多于[68Ga]Ga-DOTATATE(457 vs. 291,P = 0.006),淋巴结病灶数也显著更多(30 vs. 22,P = 0.011)。
- 肿瘤摄取相当,但除十二指肠外,[18F]AlF-NOTA-LM3在所有部位病灶的TBR均显著更高。
关键数值与推荐
- 局灶性摄取高于周围本底活性且无法用生理性摄取解释者被视为NET病灶。
- 比较病灶数量、肿瘤摄取和肿瘤/本底比值(TBR)。
- 对于结果不一致的患者,比较[68Ga]Ga-DOTATATE和[18F]AlF-NOTA-LM3检出的最小病灶尺寸(在配准CT上测量)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 18F-labelled somatostatin receptor (SSTR) analogs offer several advantages over 68Ga in terms of yield, cost, spatial resolution and detection rate. This study presents an interim analysis of a prospective trial designed to assess the safety, biodistribution and dosimetry of [18F]AlF-NOTA-LM3, and compare its diagnostic efficacy and clinical management outcomes with [68Ga]Ga-DOTATATE or [68Ga]Ga-NODAGA-LM3 in patients with well-differentiated NETs. METHODS: Twenty-one patients with histologically confirmed well-differentiated neuroendocrine tumors (G1 and G2) were prospectively recruited. The first eight patients underwent serial PET scans at 5, 15, 30, 45, 60, and 120 min after [18F]AlF-NOTA-LM3 injection to assess biodistribution and dosimetry. The remaining patients underwent whole-body PET/CT scans. [18F]AlF-NOTA-LM3 and [68Ga]Ga-DOTATATE PET/CT were done within a week, with a minimum 24-hour interval between the two scans. Focal uptake above the surrounding background activity and could not be explained by physiologic uptake was considered lesions of NETs. Lesion number, tumor uptake, and tumor-to-background ratio (TBR) were compared. In patients with discrepant findings, the size of the smallest lesions (measured on coregistered CT) detected on [68Ga]Ga-DOTATATE and [18F]AlF-NOTA-LM3 was compared. RESULTS: [18F]AlF-NOTA-LM3 was safe and well-tolerated. Physiological uptake of [18F]AlF-NOTA-LM3 was significantly lower than that of [68Ga]Ga-DOTATATE in abdominal organs and bone marrow, but higher in blood pool and lung. The mean effective dose was 0.024 ± 0.014 mSv/MBq. [18F]AlF-NOTA-LM3 detected significantly more liver lesions (457 vs. 291, P = 0.006) and lymph node lesions (30 vs. 22, P = 0.011) compared to [68Ga]Ga-DOTATATE. The tumor uptake was comparable, but TBR was significantly higher with [18F]AlF-NOTA-LM3 for lesions from all sites except for the duodenum. The size of the minimum liver lesions (0.54 ± 0.15 vs. 1.01 ± 0.49, P<0.001) and lymph node lesions (0.50 ± 0.19 vs. 1.26 ± 0.86, P = 0.024) detected on [18F]ALF-NOTA-LM3 were significantly smaller than those detected on [68Ga]Ga-DOTATATE. CONCLUSION: [18F]AlF-NOTA-LM3 shows favorable biodistribution, higher spatial resolution and superior performance than [68Ga]Ga-DOTATATE in detecting liver and lymph node metastases, with higher TBR. Notably, it is the first SSTR analog to show superiority in detecting lymph node lesions when compared to [68Ga]Ga-DOTATATE. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT06056362.
引用
- Liu M, Ren C, Zhang H, et al. Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NOTA-LM3 and head-to-head comparison with [68Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial. Eur J Nucl Med Mol Imaging. 2024. PMID: 38878175. doi:10.1007/s00259-024-06790-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。